

**Main Questions and Answers Related to
the First Quarter Results of Fiscal Year Ending March 2022**

- Q: Which sub-segments are the drivers for revision of the consolidated financial forecast?
- A: In Healthcare segment, Life Science business is expected to be the driver together with the strong Medical Systems business and Bio-CDMO business by the growth of cell culture media business. In Materials segment, both Electronic Materials business and Display Materials business will contribute thanks to the strong demand of semiconductor market and the continuous rise in demand for monitors, tablets and TVs. In Imaging segment, we reflected trend of the sales increase for *instax* series mainly in North America.
- Q: Tell us about the assumptions for the remaining Q2 to Q4 regarding the consolidated earnings forecast for operating income.
- A: As the progress in Q1 was favorable we considered the possibility of further increasing the upward revision of the forecast. However, as the uncertainty risks remain in the business environment such as tight supply of semiconductor materials, increasing distribution costs, rising raw material prices of aluminum and silver and the COVID-19 pandemic, the forecast revision was set at the minimum level to be achieved.
- Q: Tell us about the Medical Systems business performance of FUJIFILM Corporation and newly consolidated FUJIFILM Healthcare Corporation (FHC).
- A: The performance of both companies are progressing well and synergy strategies are starting to work successfully through cross-selling products and upgrading FHC's large-scale modality equipments with Fujifilm's medical IT technology. FHC will be further expanding its global sales by leveraging Fujifilm's overseas sales channels.
- Q: Tell us about potential impact in the company's Medical Systems business from the government procurement guidelines recently issued by the Chinese government instructing local authorities to buy locally manufactured products.
- A: No significant impact to the business is expected as we have already taken measures such as transferring some of the production of X-ray and ultrasound equipments to China.